Summit stock crashes as Akeso shares bispecific's first overall survival data in Keytruda head-to-head trial - Fierce Pharma
Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF bispecific ivonescimab—and investors in the company's partner Summit Ther | Akeso has shared for the first time overall survival data f…
Comments